Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Karl Hostetler
University of California, San Diego, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Antiva Biosciences, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Hostetler is the founder of Antiva Biosciences, Inc. (Antiva) and holds (b)(4) equity interest. In addition, he receives compensation for providing up to 10 hours of advisory support per month. Antiva is a company developing novel, localized therapeutics for the treatment of disease caused by HPV infection. The company licensed technology from the University of which Dr. Hostetler is a co-inventor. The technology licensed contains both HPV and HIV compounds, though Antiva is not commercializing any of the HIV compounds. This project is to utilize novel synthetic chemistry to develop aliphatic tenofovir prodrugs designed to enhance cellular uptake and to provide prolonged intracelullar exposures to molecules with potent antiviral activity.
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles
Project Narrative In this application we propose to utilize novel synthetic chemistry to develop a series of aliphatic tenofovir prodrugs designed to greatly enhance cellular uptake and to provide prolonged intracellular exposure to molecules with potent antiviral activity. We will further extend systemic exposure to these compounds by delivering them in slow-release nanoparticle formulations. We believe that with this ?dual-modulation? of drug presentation we will provide systemic exposure to therapeutic concentrations of highly active antiviral compounds for periods of at least four weeks following intramuscular injection.
Filed on August 10, 2017.
Tell us what you know about Karl Hostetler's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Karl Hostetler”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Karl Hostetler | University of California, San Diego | Conflict of Interest | Antiva Biosciences, Inc. | $60,000 - $79,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.